Immune Epitopes of SARS-CoV-2 Spike Protein and Considerations for Universal Vaccine Development

Immunohorizons. 2024 Mar 1;8(3):214-226. doi: 10.4049/immunohorizons.2400003.

Abstract

Despite the success of global vaccination programs in slowing the spread of COVID-19, these efforts have been hindered by the emergence of new SARS-CoV-2 strains capable of evading prior immunity. The mutation and evolution of SARS-CoV-2 have created a demand for persistent efforts in vaccine development. SARS-CoV-2 Spike protein has been the primary target for COVID-19 vaccine development, but it is also the hotspot of mutations directly involved in host susceptibility and virus immune evasion. Our ability to predict emerging mutants and select conserved epitopes is critical for the development of a broadly neutralizing therapy or a universal vaccine. In this article, we review the general paradigm of immune responses to COVID-19 vaccines, highlighting the immunological epitopes of Spike protein that are likely associated with eliciting protective immunity resulting from vaccination in humans. Specifically, we analyze the structural and evolutionary characteristics of the SARS-CoV-2 Spike protein related to immune activation and function via the TLRs, B cells, and T cells. We aim to provide a comprehensive analysis of immune epitopes of Spike protein, thereby contributing to the development of new strategies for broad neutralization or universal vaccination.

Publication types

  • Review

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Epitopes
  • Humans
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus* / genetics
  • Vaccine Development

Substances

  • spike protein, SARS-CoV-2
  • Spike Glycoprotein, Coronavirus
  • COVID-19 Vaccines
  • Epitopes